Biosimilars in pediatrics

Area of Science:

• Pharmaceutical Science
• Pharmacoeconomics
• Pediatric Medicine

Background:

• Biosimilars are highly similar biological medicines to existing originator drugs, offering significant cost savings.
• Regulatory bodies rigorously assess biosimilars for quality, safety, and efficacy, ensuring comparability to reference products.
• The potential of biosimilars to improve healthcare resource allocation and patient affordability is substantial.

Purpose of the Study:

• To review the current evidence supporting the use of biosimilars in pediatric populations.
• To discuss the ongoing debates surrounding indication extrapolation and interchangeability of biosimilars.
• To identify challenges hindering biosimilar adoption and propose strategies for improvement.

Main Methods:

• Literature review of regulatory approvals and scientific publications on biosimilars.
• Analysis of economic benefits and healthcare resource implications of biosimilar use.
• Examination of post-marketing surveillance data and clinical experience with biosimilars.

Main Results:

• Structural and functional equivalence, along with post-marketing data, supports biosimilar use in pediatrics.
• Extrapolation of indications and interchangeability remain areas of active discussion and research.
• Challenges include regulatory inconsistencies and public mistrust stemming from misinformation.

Conclusions:

• Biosimilars present a valuable therapeutic option with proven safety and efficacy, particularly in pediatrics.
• Addressing regulatory heterogeneity and combating misinformation are crucial for maximizing biosimilar access.
• Enhanced education and clear public policies are essential for the successful integration of biosimilars into healthcare systems.